Looking to accelerate the commercialisation of your digital health solution? Join us for an evening of insights and networking on Wednesday, 6th November to explore how non-dilutive funding can help drive your innovation forward.

At this event, we’ll explore key strategies for securing non-dilutive commercialization funding that can benefit all players in the health tech ecosystem. Our expert panel will share insights on effectively framing your value proposition, understanding what buyers—particularly in hospitals—are seeking, and navigating the non-dilutive investment landscape. This is a valuable opportunity for anyone involved in health tech to gain insights and enhance their understanding of funding opportunities.

Led by Adam Wardell, CEO and Founder of Previsior, the conversation will feature three industry experts:

Anne O'Neill, Director, Enterprise, International Partnerships and Clinical Trials, Office for Health and Medical Research, NSW Government
Kim Smyth, General Manager Investment, ANDHealth
Carl Runde, Chief Financial Officer and Company Secretary, Atmo Biosciences

We’ll conclude with a Q&A to provide answers to your most pressing questions.

After the panel, join us for drinks and snacks, and connect with key players in the field. Don’t miss the chance to connect with industry leaders and peers.

Whether you're new to non-dilutive funding or looking for expert advice, this event will provide practical insights on navigating the landscape and maximising your chances of success.

Meet the speakers

Adam Wardell, CEO and Founder, Previsior

Adam brings over 25 years of experience in health and innovation, spanning clinical care, commercial excellence and a track record of innovation success. Adam established the health-focused consultancy ‘Previsior’ to guide innovators and industry on creating change within the health landscape, including commercial planning, go-to-market strategy and business development. Adam has also supported ANDHealth since its foundation and has contributed in a variety of roles, including Executive in Residence. By providing deep insights, facilitating effective business partnering, and applying transformational practices, Adam has shaped many health innovations to deliver commercially sustainable outcomes and enable patient access to new therapy options. Adam is a member of AICD and holds an MBA and Bachelor of Pharmacy.

Anne O'Neill, Director, Enterprise, International Partnerships and Clinical Trials, Office for Health and Medical Research, NSW Government

Anne has over 25 years’ experience in the health, medical research and policy sectors. She is responsible for leading the development and implementation of major policies and programs to enhance medical research capacity in NSW, and raise the profile of NSW research and development nationally and internationally. She was the architect of the NSW Medical Device Fund and co-designed the NSW Commercialisation Training Program with Cicada Innovations – both have been critical to accelerating the development of NSW intellectual property and the next generation of innovators and entrepreneurs in NSW. Anne holds a Bachelor of Science (Physiology and Pharmacology) (Hons) and an Executive Masters of Public Administration (ANZSOG).

Kim Smyth, General Manager Investment, ANDHealth

Kim is the GM of Investment for ANDHealth, where she leads non-dilutive ANDHealth+ and digital health component of CUREator+ programs (in partnership with Brandon BioCatalyst. Kim brings a global track record in digital health commercialisation, innovation strategy, and digital transformation to this role. She began her career with Braxton/ Deloitte in North America and Europe, before taking operational roles at an e-learning startup and The Body Shop, where she established the company’s first direct-to-consumer analytics and relationship management function. She came to healthcare to design a novel, data-driven support program for cardiovascular patients for AstraZeneca Australia, and in 2015 she helped establish a CTO office in Silicon Valley. She led a team to scout 300+ novel startups and deliver more than a dozen proof-of-concept pilots, including the company's first fully virtual clinical trials. She has advised digital health start-ups both locally and internationally on partnership and commercial strategy.

Carl Runde, Chief Financial Officer and Company Secretary, Atmo Biosciences

Carl Runde is a finance professional with over two decades of experience in the international medical device industry, specializing in corporate financial analysis, valuation modeling, and strategic business planning.

Having held key positions such as Chief Financial Officer at Atmo Biosciences, Vice President at ResMed, and Director at Osteopore Limited, Carl has demonstrated a track record of delivering value as a finance partner to various functions including commercial operations, research and development, human resources, and corporate strategy. His academic background includes a PhD from the University of Sydney, an MBA from Macquarie Graduate School of Management, and Bachelor's degrees in International Relations, Economics, Economic History, Political Studies, English, and Law from the University of the Witwatersrand. Carl Runde's expertise lies in driving inclusive approaches to sustainable growth and stakeholder value creation, aligning financial strategies with organizational objectives, and leveraging international practical knowledge to support business operations and decision-making.

About ANDHealth

ANDHealth is Australia’s leading provider of accelerator, incubator and commercialisation programs for digital health technology companies. Since 2017 ANDHealth has worked with over 935 digital & connected health companies across Australia. They harness a unique, non-profit, cooperative commercialisation model to facilitate industry investment and support for high growth digital and connected health companies. They provide high-performing intermediary services, accelerator and incubator programs to identify, assess and accelerate the growth of digital and connected health startups across Australia.

ANDHealth has market-leading capabilities in identification, assessment and acceleration of digital and connected health technologies from idea to global market uptake. They design and deliver proven programs proven which support startup founders and CEOs to navigate the rapidly evolving global market for digital and connected health solutions.

ANDHealth’s flagship program methodology, ANDHealth+ (AH+), is Australia’s only program proven to support the translation and commercialisation of proof-of-concept digital and connected health technologies through clinical trials, commercial pilots, investment and implementation, ultimately resulting in the delivery of new products and services to patients. Approximately 90% of AH+ alumni are now generating revenues clearly demonstrating the program’s ability to foster growth, de-risking and commercialisation.

About the Cicada HealthTech Hub

Located inside Westmead Health and Innovation District, The Cicada HealthTech Hub will be a home to early stage health companies, a space for collaboration and commercialisation activation, and a landing pad for industry seeking solutions to their research and business challenges. Helping to contribute to the vision of making Westmead a world-class innovation district in health and education. The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District.

The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.

The Cicada Health Tech Hub delivers several new health-focused program alongside Australasia’s leading life science VC firm, Brandon Capital.